• The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.

• The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.

• The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.

• Participants must be at least 6 months and no more than 5 years (after completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4/6, or immunotherapy). Participants may still be taking endocrine therapy and/or trastuzumab.

• The participant must be able to understand, speak, read, and write in English or Spanish.